Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine

David Osoba, Donald W Northfelt, David W. Budd, David Himmelberger

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The purpose of this study was to determine whether health-related quality of life (HRQL) would be improved in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma treated by pegylated-liposomal doxorubicin (PLD) as compared to those treated by a conventional combination of doxorubicin, bleomycin, and vincristine (ABV). One hundred thirty-three patients received PLD and 125 patients received ABV every 2 weeks with a planned total of 6 cycles. Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment. Twenty-two items, involving nine domains, were analyzable. While on treatment, PLD-treated patients with partial clinical responses achieved statistically significant greater improvement (compared to baseline) in general health than did ABV-treated patients with partial clinical responses (p = 0.008). By the end of treatment, the overall group of patients receiving PLD showed statistically significant greater improvement in pain and energy/fatigue than did the group receiving ABV (p = 0.01-0.002). In addition, duration of clinically significant improvement in global QL was longer in the PLD arm.

Original languageEnglish (US)
Pages (from-to)573-580
Number of pages8
JournalCancer Investigation
Volume19
Issue number6
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Bleomycin
Vincristine
Doxorubicin
Acquired Immunodeficiency Syndrome
Quality of Life
Therapeutics
liposomal doxorubicin
Fatigue
Pain
Health

Keywords

  • Acquired immunodeficiency syndrome (AIDS)
  • Bleomycin
  • Doxorubicin
  • Health-related quality of life
  • Kaposi's sarcoma
  • Pegylated-liposomal doxorubicin
  • Vincristine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{435c0cc39fe947ad8597d2d6e00979b1,
title = "Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma: A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine",
abstract = "The purpose of this study was to determine whether health-related quality of life (HRQL) would be improved in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma treated by pegylated-liposomal doxorubicin (PLD) as compared to those treated by a conventional combination of doxorubicin, bleomycin, and vincristine (ABV). One hundred thirty-three patients received PLD and 125 patients received ABV every 2 weeks with a planned total of 6 cycles. Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment. Twenty-two items, involving nine domains, were analyzable. While on treatment, PLD-treated patients with partial clinical responses achieved statistically significant greater improvement (compared to baseline) in general health than did ABV-treated patients with partial clinical responses (p = 0.008). By the end of treatment, the overall group of patients receiving PLD showed statistically significant greater improvement in pain and energy/fatigue than did the group receiving ABV (p = 0.01-0.002). In addition, duration of clinically significant improvement in global QL was longer in the PLD arm.",
keywords = "Acquired immunodeficiency syndrome (AIDS), Bleomycin, Doxorubicin, Health-related quality of life, Kaposi's sarcoma, Pegylated-liposomal doxorubicin, Vincristine",
author = "David Osoba and Northfelt, {Donald W} and Budd, {David W.} and David Himmelberger",
year = "2001",
doi = "10.1081/CNV-100104284",
language = "English (US)",
volume = "19",
pages = "573--580",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Effect of treatment on health-related quality of life in acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma

T2 - A randomized trial of pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine

AU - Osoba, David

AU - Northfelt, Donald W

AU - Budd, David W.

AU - Himmelberger, David

PY - 2001

Y1 - 2001

N2 - The purpose of this study was to determine whether health-related quality of life (HRQL) would be improved in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma treated by pegylated-liposomal doxorubicin (PLD) as compared to those treated by a conventional combination of doxorubicin, bleomycin, and vincristine (ABV). One hundred thirty-three patients received PLD and 125 patients received ABV every 2 weeks with a planned total of 6 cycles. Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment. Twenty-two items, involving nine domains, were analyzable. While on treatment, PLD-treated patients with partial clinical responses achieved statistically significant greater improvement (compared to baseline) in general health than did ABV-treated patients with partial clinical responses (p = 0.008). By the end of treatment, the overall group of patients receiving PLD showed statistically significant greater improvement in pain and energy/fatigue than did the group receiving ABV (p = 0.01-0.002). In addition, duration of clinically significant improvement in global QL was longer in the PLD arm.

AB - The purpose of this study was to determine whether health-related quality of life (HRQL) would be improved in patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma treated by pegylated-liposomal doxorubicin (PLD) as compared to those treated by a conventional combination of doxorubicin, bleomycin, and vincristine (ABV). One hundred thirty-three patients received PLD and 125 patients received ABV every 2 weeks with a planned total of 6 cycles. Patients completed a 30-item AIDS-related HRQL questionnaire before beginning treatment (baseline), every 2 weeks while on treatment, and about 21 days after the end of treatment. Twenty-two items, involving nine domains, were analyzable. While on treatment, PLD-treated patients with partial clinical responses achieved statistically significant greater improvement (compared to baseline) in general health than did ABV-treated patients with partial clinical responses (p = 0.008). By the end of treatment, the overall group of patients receiving PLD showed statistically significant greater improvement in pain and energy/fatigue than did the group receiving ABV (p = 0.01-0.002). In addition, duration of clinically significant improvement in global QL was longer in the PLD arm.

KW - Acquired immunodeficiency syndrome (AIDS)

KW - Bleomycin

KW - Doxorubicin

KW - Health-related quality of life

KW - Kaposi's sarcoma

KW - Pegylated-liposomal doxorubicin

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=0034924045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034924045&partnerID=8YFLogxK

U2 - 10.1081/CNV-100104284

DO - 10.1081/CNV-100104284

M3 - Article

C2 - 11486699

AN - SCOPUS:0034924045

VL - 19

SP - 573

EP - 580

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 6

ER -